Original Articles Open access

Anticancer effects of punicalagin and 5-fluorouracil on laryngeal squamous cell carcinoma: an in vitro study

Authors

Published
22 February 2024
Section
Original Articles
DOI
10.4081/itjm.2024.1699

Abstract

The purpose of this study was to assess the apoptotic effects of punicalagin alone and in combination with 5-fluorouracil (5-FU) on laryngeal squamous cell carcinoma (Hep-2) cell line. Hep-2 cells were cultured and divided into four groups: Group 1 received no therapy and served as control, Group 2 received 5-FU only, Group 3 received punicalagin only, and Group 4 received a combination of 5-FU and punicalagin. After 48 hours of incubation, cellular changes were examined under an inverted microscope. The methyl thiazolyl tetrazolium assay, caspase-3 gene level, and vascular endothelial growth factor (VEGF) level were assessed. The control group showed the highest mean value of cancer cell proliferation rate (1.595±0.58), followed by the punicalagin group (1.263±0.447), then the 5-FU group (0.827±0.256), while the combination group showed the lowest proliferation rate (0.253±0.111). The combination group showed the highest mean value of caspase-3 concentration (3.177±0.736), followed by the 5-FU group (1.830±0.646), and punicalagin group (0.741±0.302), while the control group showed the lowest mean value (0.359±0.117). Regarding VEGF levels, the control group had a statistically significant higher mean value, followed by the punicalagin and 5-FU groups, and finally, the combination group which showed the lowest value. Punicalagin exerts an anticancer effect through anti-proliferative action and induction of apoptosis on Hep-2 cell line. Combining punicalagin with 5-FU potentiates its anti-proliferative, apoptotic, and anti-angiogenic actions. It, further, helps in mitigating the putative side effects of 5-FU by reducing the dose required for its therapeutic effects.

Keywords

References

  1. Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primer 2020;6. DOI: https://doi.org/10.1038/s41572-020-00224-3
  2. Gao P, Gong L, Wang X. Induction chemotherapy in patients with resectable laryngeal cancer: A meta-analysis. Mol Clin Oncol 2018;9:155-62. DOI: https://doi.org/10.3892/mco.2018.1645
  3. Li Z, Li T, Zhang P, Wang X. A practical online prediction platform to predict the survival status of laryngeal squamous cell carcinoma after 5 years. Am J Otolaryngol 2024;45:104209. DOI: https://doi.org/10.1016/j.amjoto.2023.104209
  4. Gamez ME, Blakaj A, Zoller W, et al. Emerging Concepts and Novel Strategies in Radiation Therapy for Laryngeal Cancer Management. Cancers 2020;12:1651. DOI: https://doi.org/10.3390/cancers12061651
  5. Megwalu UC, Sikora AG. Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg 2014;140:855-60. DOI: https://doi.org/10.1001/jamaoto.2014.1671
  6. Haigentz MJr, Silver CE, Hartl DM, et al. Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin Pharmacother 2010;11:1305-16. DOI: https://doi.org/10.1517/14656561003749256
  7. Iizuka Y, Yoshimnura M, Inokuchi H, et al. Recurrence patterns after postoperative radiotherapy for squamous cell carcinoma of the pharynx and larynx. Acta Otolaryngol (Stockh.) 2015;135:96-102. DOI: https://doi.org/10.3109/00016489.2014.949848
  8. Wang D, Yu D, Liu X, et al. Targeting laryngeal cancer cells with 5-fluorouracil and curcumin using mesoporous silica nanoparticles. Technol Cancer Res Treat 2020;19:1533033820962114 DOI: https://doi.org/10.1177/1533033820962114
  9. Echanique KA, Evans LK, Han AY, et al. Cancer of the Larynx and Hypopharynx. Head Neck Cancer 2021;35:933-47. DOI: https://doi.org/10.1016/j.hoc.2021.05.005
  10. Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol 2011;4:687-99. DOI: https://doi.org/10.1111/j.1751-7915.2010.00221.x
  11. Iqbal J, et al. Plant-derived anticancer agents: A green anticancer approach. Asian Pac J Trop Biomed 2017;7:1129-50. DOI: https://doi.org/10.1016/j.apjtb.2017.10.016
  12. Sharma P, McClees SF, Afaq F. Pomegranate for Prevention and Treatment of Cancer: An Update. Molecules 2017;22:177. DOI: https://doi.org/10.3390/molecules22010177
  13. Syed DN, Chamcheu JC, Adhami VM, Mukhtar H. Pomegranate extracts and cancer prevention: Molecular and cellular activities. Anticancer Agents Med Chem 2013;13:1149-61. DOI: https://doi.org/10.2174/1871520611313080003
  14. Lin LT, Chen TY, Lin SC, et al. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol 2013;13:187. DOI: https://doi.org/10.1186/1471-2180-13-187
  15. Tang J, Li B, Hong S, et al. Punicalagin suppresses the proliferation and invasion of cervical cancer cells through inhibition of the β-catenin pathway. Mol Med Rep 2017;161439-44.
  16. Lee CJ, Chen LG, Liang WL, Wang CC. Anti-inflammatory effects of Punica granatum Linne in vitro and in vivo. Food Chem 2010;118:315-22. DOI: https://doi.org/10.1016/j.foodchem.2009.04.123
  17. Bialonska D, Ramnani P, Kasimsetty SG, et al. The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int J of Food Microbiol 2010;140:175-82. DOI: https://doi.org/10.1016/j.ijfoodmicro.2010.03.038
  18. Adams LS, Seeram NP, Aggarwal BB, Y, et al. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006;54:980-5. DOI: https://doi.org/10.1021/jf052005r
  19. Overbergh L, Giulietti A, Valckx D, et al. The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 2003;1:33-43.
  20. Kulkarni AP, Mahal HS, Kapoor S, Aradhya SM. In Vitro Studies on the Binding, Antioxidant, and Cytotoxic Actions of Punicalagin. J Agric Food Chem 2007;55:1491-500. DOI: https://doi.org/10.1021/jf0626720
  21. Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005;16:360-67. DOI: https://doi.org/10.1016/j.jnutbio.2005.01.006
  22. Liu W, Ou Y, Yang Y, et al. Inhibitory Effect of Punicalagin on Inflammatory and Angiogenic Activation of Human Umbilical Vein Endothelial Cells. Front Pharmacol 2021;12. DOI: https://doi.org/10.3389/fphar.2021.727920
  23. Cao D, Zhu G-Y, Lu Y, et al. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Biomed Pharmacother 2020;129:110462. DOI: https://doi.org/10.1016/j.biopha.2020.110462
  24. Mirzaei S, Zarrabi A, Hashemi F, et al. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants 2021;10. DOI: https://doi.org/10.3390/antiox10030349
  25. Odell E, et al. European Laryngological Society position paper on laryngeal dysplasia Part I: aetiology and pathological classification. Eur Arch Otorhinolaryngol 2021;278:1717-22. DOI: https://doi.org/10.1007/s00405-020-06403-y
  26. Berdowska I, Matusiewicz M, Fecka I. Punicalagin in Cancer Prevention—Via Signaling Pathways Targeting. Nutrients 2021;13. DOI: https://doi.org/10.3390/nu13082733
  27. Souchon EA, Copeland EM, Watson P, Dudrick SJ. Intravenous hyperalimentation as an adjunct to cancer chemotherapy with 5-fluorouracil. J Surg Res 1975;18:451-4. DOI: https://doi.org/10.1016/0022-4804(75)90108-0
  28. Zhang L, Chinnathambi A, Alharbi SA, et al. Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway. Saudi J Biol Sci 2020;27:1100-6. DOI: https://doi.org/10.1016/j.sjbs.2020.02.015
  29. Anitha A, Sreeranganathan M, Chennazhi KP, et al. In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. Eur J Pharm Biopharm 2014;88:238-51. DOI: https://doi.org/10.1016/j.ejpb.2014.04.017
  30. Ghiringhelli F, Apetoh L. Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives. Biomed J 2015;38:111-6. DOI: https://doi.org/10.4103/2319-4170.130923
  31. Huang T, Zhang X, Wang H. Punicalagin inhibited proliferation, invasion and angiogenesis of osteosarcoma through suppression of NF‑κB signaling. Mol Med Rep 2020;22:2386-94. DOI: https://doi.org/10.3892/mmr.2020.11304
  32. Suruli D, Mirza FBS, Kottaiswamy GJCRA, et al. Naringin and 5-fluorouracil suppress inflammatory Cytokines in human skin cancer cell line. Int J Res Pharm Sci 2021;12:729-33. DOI: https://doi.org/10.26452/ijrps.v12i1.4172
  33. Yan C, et al. Punicalagin attenuates palmitate-induced lipotoxicity in HepG2 cells by activating the Keap1-Nrf2 antioxidant defense system. Mol Nutr Food Res 2016;60:1139-49. DOI: https://doi.org/10.1002/mnfr.201500490

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2024 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.